The NIH, FDA and Bill and Melinda Gates Foundation are working with a San Francisco startup whose calling card is an AI-enabled engine that renders patient data unidentifiable by reproducing it in synthetic versions.

Last Tuesday the FDA posted an action plan telling how it will evaluate AI for medical applications going forward. Three days later the agency officially proposed letting numerous products through without review. 

One turnoff is remote food monitoring. Another is real-time feedback—whether from a live healthcare professional or an AI algorithm.

If the hospitals of America’s most populous city are any sort of bellwether, CMS is going to have its hands full trying to enforce compliance with the Trump Administration’s executive order on price transparency.

The national average increase over the study period was 760%—from 2.0 pediatric hospitalizations per 100,000 persons in May to 17.2 in November.

Researchers have found nonmedical working professionals bearing significantly more depression and anxiety these days than doctors and nurses working with or near COVID-19 patients.

A noted AI researcher and educator who was drawn to the field by its escalating penetration of “the mysteries of perception and cognition” has found a sort of missing link in its evolution. 

The tools could be used by primary care providers to head off adverse respiratory events and suboptimal healthcare utilization. 

An AI application that interprets MRI scans of the brain for signs or confirmation of injury has received 510(k) clearance from the FDA.

The agency has posted an interactive map showing the locations of drug distributors that have recently received shipments of two monoclonal antibody medications good for treating COVID-19.